According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

Merck says the expansion in Durham is part of more than $12 billion the company has invested in U.S. manufacturing and ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...

With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...

while Merck & Co., based in New Jersey, currently is the only manufacturer of BCG (TICE® BCG) in the U.S. ImmunityBio has been awarded multiple patents covering the composition and methods of use ...

This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer. ImmunityBio said that Merck’s TICE BCG shortages have ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication. The FDA has approved an expanded access program that will provide an alternative ...